The takeover of AnHeart centres on advancing the latter’s targeted lung cancer project taletrectinib.

Three recently added trials take Merck & Co’s tally of phase 3 sacituzumab tirumotecan studies to six.

The company’s post-Seagen ADC portfolio features overlapping targets with differing payloads.

An “optimised formulation” of bezuclastinib looks promising, but the safety question remains open.

Nearly two thirds of key oncology filings are expedited; and what about the ones that aren’t?

A look at big oncology deals since 2016 finds outright success stories hard to come by. 

Approval on the basis of Flaura2 is part of a double success for Astra's Tagrisso, which has also scored in Laura.